Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway

Cell Death and Differentiation

Volumn 14, Issue 3, 2007, Pages 511-523

  Bifsha, P ^a   Landry, K ^a   Ashmarina, L ^a   Durand, S ^a   Seyrantepe, V ^a   Trudel, S ^a   Quiniou, C ^a   Chemtob, S ^a   Xu, Y ^b   Gravel, R A ^b   Sladek, R ^c   Pshezhetsky, A V ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE PROTEINASE INHIBITOR; MESSENGER RNA; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; SMALL INTERFERING RNA; UBIQUITIN THIOLESTERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GALACTOSIALIDOSIS; GANGLIOSIDOSIS; GAUCHER DISEASE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYSOSOME STORAGE DISEASE; MORQUIO SYNDROME; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SANDHOFF DISEASE; SIALIC ACID STORAGE DISEASE; SIALIDOSIS; SKIN FIBROBLAST; UBIQUITINATION;

ANIMALS; APOPTOSIS; CYSTEINE PROTEINASE INHIBITORS; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEUCINE; LYSOSOMAL STORAGE DISEASES; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN; UBIQUITIN; UBIQUITIN THIOLESTERASE;

EID: 33847076127     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402013     Document Type: Article

References (42)

1. Zhan SS, Beyreuther K, Schmitt HP. Neuronal ubiquitin and neurofilament expression in different lysosomal storage disorders. Clin Neuropathol 1992; 11: 251-255.
2. Heuer GG, Passini MA, Jiang K, Parente MK, Lee VM, Trojanowski JQ et al. Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible. Ann Neurol 2002; 52: 762-770.
3. Higashi Y, Murayama S, Pentchev PG, Suzuki K. Cerebellar degeneration in the Niemann-Pick type C mouse. Acta Neuropathol (Berl) 1993; 85: 175-184.
4. Oya Y, Nakayasu H, Fujita N, Suzuki K, Suzuki K. Pathological study of mice with total deficiency of sphingolipid activator proteins (SAP knockout mice). Acta Neuropathol (Berl) 1998; 96: 29-40.
5. Bonifacino JS, Traub LM. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 2003; 72: 395-447.
6. Huang JQ, Trasler JM, Igdoura S, Michaud J, Hanal N, Gravel RA. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 1997; 6: 1879-1885.
7. Zhou J, Cox NR, Ewald SJ, Morrison NE, Basker HJ. Evaluation of GM1 ganglioside-mediated apoptosis in feline thymocytes. Vet Immunol Immunopathol 1998; 66: 25-42.
8. Finn LS, Zhang M, Chen SH, Scott CR. Severe type II Gaucher disease with ichthyosis, arthrogryposis and neuronal apoptosis: Molecular and pathological analyses. Am J Med Genet 2000; 91: 222-226.
9. Im DS, Heise CE, Nguyen T, O'Dowd BF, Lynch KR. Identification of a molecular target of psychosine and its role in globoid cell formation. J Cell Biol 2001; 153: 429-434.
10. Lozano J, Morales A, Cremesti A, Fuks Z, Tilly JL, Schuchman E et al. Niemann-Pick Disease versus acid sphingomyelinase deficiency. Cell Death Differ 2001; 8: 100-103.
11. Jatana M, Giri S, Singh AK. Apoptotic positive cells in Krabbe brain and induction of apoptosis in rat C6 glial cells by psychosine. Neurosci Lett 2002; 330: 183-187.
12. Cho S, Dawson PE, Dawson G. Role of palmitoyl-protein thioesterase in cell death: Implications for infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol 2001; 5: 53-55.
13. Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: A possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001; 81: 1319-1328.
14. Hesselink RP, Wagenmakers AJ, Drost MR, Van der Vusse GJ. Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II. Biochim Biophys Acta 2003; 1637: 164-170.
15. Park M, Helip-Wooley A, Thoene J. Lysosomal cystine storage augments apoptosis in cultured human fibroblasts and renal tubular epithelial cells. J Am Soc Nephrol 2002; 13: 2878-2887.
16. Tardy C, Andrieu-Abadie N, Salvayre R, Levade T. Lysosomal storage diseases: Is impaired apoptosis a pathogenic mechanism? Neurochem Res 2004; 29: 871-880.
17. Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 2000; 97: 10954-10959.
18. Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y et al. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 2002; 109: 1215-1221.
19. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-452.
20. Phaneuf D, Wakamatsu N, Huang JQ, Borowski A, Peterson AC, Fortunato SR et al. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 1996; 5: 1-14.
21. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004; 279: 13256-13264.
22. Doherty FJ, Osborn NU, Wassell JA, Heggie PE, Laszlo L, Mayer RJ. Ubiquitin-protein conjugates accumulate in the lysosomal system of fibroblasts treated with cysteine proteinase inhibitors. Biochem J 1989; 263: 47-55.
23. Laszlo L, Doherty FJ, Osborn NU, Mayer RJ. Ubiquitinated protein conjugates are specifically enriched in the lysosomal system of fibroblasts. FEBS Lett 1990; 261: 365-368.
24. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 2003; 12: 1945-1958.
25. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997; 94: 855-860.
26. Varshavsky A. The ubiquitin system. Trends Biochem Sci 1997; 22: 383-387.
27. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292: 1552-1555.
28. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989; 246: 670-673.
29. Olerud JE, Chiu DS, Usui ML, Gibran NS, Ansel JC. Protein gene product 9.5 is expressed by fibroblasts in human cutaneous wounds. J Invest Dermatol 1998; 111: 565-572.
30. Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999; 23: 47-51.
31. Kurihara LJ, Kikuchi T, Wada K, Tilghman SM. Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia. Hum Mol Genet 2001; 10: 1963-1970.
32. Castegna A, Thongboonkerd V, Klein J, Lynn BC, Wang YL, Osaka H et al. Proteomic analysis of brain proteins in the cracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins. J Neurochem 2004; 88: 1540-1546.
33. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000; 408: 101-106.
34. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury Jr PT. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002; 111: 209-218.
35. Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem 2004; 90: 379-391.
36. Yang Y, Yu X. Regulation of apoptosis: The ubiquitous way. FASEB J 2003; 17: 790-799.
37. Kwon J, Wang YL, Setsuie R, Sekiguchi S, Sato Y, Sakurai M et al. Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testis. Am J Pathol 2004; 165: 1367-1374.
38. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002; 8: 192-195.
39. Bonin M, Poths S, Osaka H, Wang YL,Wada K, Riess O. Microarray expression analysis of gad mice implicates involvement of Parkinson's disease associated UCH-L1 in multiple metabolic pathways. Brain Res Mol Brain Res 2004; 126: 88-97.
40. Harada T, Harada C, Wang YL, Osaka H, Amanai K, Tanaka K et al. Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. Am J Pathol 2004; 164: 59-64.
41. Pshezhetsky AV, Potier M. Association of N-acetylgalactosamine-6-sulfate sulfatase with the multienzyme lysosomal complex of beta-galactosidase, cathepsin A, and neuraminidase. Possible implication for intralysosomal catabolism of keratan sulfate. J Biol Chem 1996; 271: 28359-28365.
42. Rodgers KJ, Dean RT. Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int J Biochem Cell Biol 2003; 35: 716-727.